文献速递生殖医学

成人卵巢经阿霉素、博来霉素、长春花碱和达卡巴嗪(ABVD)化疗后非生长卵泡密度增加

Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary.
PubMed 文献 · Hum Reprod · 2016-12-05

该研究比较了ABVD或OEPA-COPDAC化疗后霍奇金淋巴瘤患者卵巢组织中卵泡密度、形态及体外发育潜能。ABVD治疗组非生长卵泡密度高于未化疗、OEPA-COPDAC治疗及产科对照组织,但体外发育至次级卵泡受限。

要点

  • ABVD治疗组非生长卵泡密度(230 ± 17)高于未治疗组(110 ± 54)、OEPA-COPDAC组(50 ± 27)和产科组织(20 ± 4)(P < 0.01)。
  • ABVD治疗组和青少年未治疗组常见双卵泡和双核非生长卵泡,OEPA-COPDAC组和产科组织未见。
  • ABVD治疗组体外培养6天后发育至次级卵泡非常有限,未治疗组与产科组织相似。

核心结论

  • ABVD化疗后卵巢非生长卵泡数量未耗竭,与临床数据显示生育力保留一致。
  • 未成熟卵泡密度在至少一种化疗后可增加也可减少,为首次报告ABVD治疗组织与未成熟人卵巢在形态和卵泡发育上的相似性。

研究设计与样本

  • 从霍奇金淋巴瘤患者获取13例卵巢活检(6例青少年和7例成人),另1例非霍奇金淋巴瘤患者活检;2例霍奇金淋巴瘤患者和1例非霍奇金淋巴瘤患者在活检前未接受治疗,其余11例霍奇金淋巴瘤患者接受ABVD或OEPA-COPDAC方案。
  • 组织进行组织学分析并与健康女性活检比较,部分患者组织体外培养6天。
  • 卵巢活检来自为生育力保存而行卵巢冷冻保存的患者以及剖宫产时的健康女性(产科组织)。

主要发现

  • 共分析6877个卵泡。
  • ABVD治疗组非生长卵泡密度为230 ± 17(均值 ± 标准误),高于未治疗组110 ± 54、OEPA-COPDAC组50 ± 27和产科组织20 ± 4(P < 0.01),卵泡密度比年龄相关模型预测值高9-21个标准差。
  • OEPA-COPDAC治疗组形态异常卵母细胞比例为52%,高于未治疗组23%、ABVD组22%和产科组织25%(P < 0.001)。
  • 体外培养中所有组均出现卵泡生长激活,但ABVD治疗组发育至次级阶段非常有限,而未治疗淋巴瘤患者组织生长与产科组织相似(未治疗组 vs ABVD组 P < 0.01,未治疗组 vs 产科组织无显著差异)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 尽管分析了大量卵泡,但数据来自少量活检。
  • 这些观察的机制尚未确定,且与未来生育力的关系尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Do the chemotherapeutic regimens of ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) or OEPA-COPDAC (combined vincristine, etoposide, prednisone, doxorubicin (OEPA) and cyclophosphamide, vincristine, prednisone, dacarbazine (COPDAC)) used to treat Hodgkin lymphoma (HL), affect the density, morphology and in vitro developmental potential of human ovarian follicles? SUMMARY ANSWER: Ovarian tissue from women treated with ABVD contained a higher density of non-growing follicles (NGFs) per cubic millimetre and increased numbers of multiovular follicles but showed reduced in vitro growth compared with patients with lymphoma who had not received chemotherapy, patients treated with OEPA-COPDAC, age-matched healthy women and age-related model-predicted values. WHAT IS KNOWN ALREADY: Chemotherapy regimens can cause a loss of follicles within the ovary, which depends on the drugs given. Early stage HL is commonly treated by ABVD, a non-alkylating regimen that apparently has ovarian sparing qualities; thus it is important to investigate the histological appearance and distribution of follicles within ABVD-treated ovarian tissue. STUDY DESIGN, SIZE, DURATION: Thirteen ovarian biopsies were obtained from HL patients (six adolescents and seven adults) and one biopsy from a non-HL patient. Two HL patients and the non-HL patient had received no treatment prior to biopsy collection. The remaining 11 HL patients received one of two regimens: ABVD or OEPA-COPDAC. Tissue was analysed histologically and compared to biopsies from healthy women, and in a subgroup of patients, tissue was cultured for 6 days in vitro. PARTICIPANTS/MATERIALS, SETTING, METHODS: Ovarian biopsies were obtained from patients undergoing ovarian cryopreservation for fertility preservation and from healthy women at the time of Caesarian section ('obstetric tissue'). Follicle number and maturity were evaluated in sections of ovarian cortical tissue, and compared to an age-related model of mean follicle density and to age-matched contemporaneous biopsies. The developmental potential of follicles was investigated after 6 days of tissue culture. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 6877 follicles were analysed. ABVD-treated tissue contained a higher density of NGFs per cubic millimetre (230 ± 17) (mean ± SEM) than untreated (110 ± 54), OEPA-COPDAC-treated (50 ± 27) and obstetric (20 ± 4) tissue (P < 0.01), with follicle density 9-21 SD higher than predicted by an age-related model. Biovular and binucleated NGFs occurred frequently in ABVD-treated and in adolescent-untreated tissue but were not observed in OEPA-COPDAC-treated or obstetric tissue, although OEPA-COPDAC-treated tissue contained a high proportion of morphologically abnormal oocytes (52% versus 23% in untreated, 22% in ABVD-treated and 25% in obstetric tissue; P < 0.001). Activation of follicle growth in vitro occurred in all groups, but in ABVD-treated samples there was very limited development to the secondary stage, whereas in untreated samples from lymphoma patients growth was similar to that observed in obstetric tissue (untreated; P < 0.01 versus ABVD-treated, NS versus obstetric). LARGE SCALE DATA: N/A LIMITATIONS, REASONS FOR CAUTION: Although a large number of follicles were analysed, these data were derived from a small number of biopsies. The mechanisms underpinning these observations have yet to be determined and it is unclear how they relate to future fertility. WIDER IMPLICATIONS OF THE FINDINGS: This study confirms that the number of NGFs is not depleted following ABVD treatment, consistent with clinical data that female fertility is preserved. Our findings demonstrate that immature follicle density can increase as well as decrease following at least one chemotherapy treatment. This is the first report of morphological and follicle developmental similarities between ABVD-treated tissue and the immature human ovary. Further experiments will investigate the basis for the marked increase in follicle density in ABVD-treated tissue. STUDY FUNDING/COMPETING INTERESTS: Funded by UK Medical Research Council Grants G0901839 and MR/L00299X/1. The authors have no competing interests.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. McLaughlin M, Kelsey TW, Wallace WH, et al. Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary. Hum Reprod. 2016. PMID: 27923859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。